Bronchodilator Drugs - Gambia | Statista Market Forecast

The revenue in the Bronchodilator Drugs market in Gambia is estimated to reach US$151.90k in 2024.
It is projected to exhibit a compound annual growth rate (CAGR 2024-2029) of 3.70%, leading to a market volume of US$182.10k by 2029.
When compared globally, United States is expected to generate the highest revenue in this market, amounting to US$17.34bn in 2024.
Bronchodilator drug usage in Gambia has seen a significant rise due to the country's high prevalence of respiratory diseases.

Definition:
Bronchodilator drugs help to dilate the airways, thus making air flow easier. They are mainly used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be applied in an acute therapy, leading to a fast and short-term relief of symptoms. Other types of bronchodilators are used for maintenance therapy in long-term treatment. Different categories of bronchodilators include beta two adrenergic agonists, anticholingergics, and theophylline.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim

Short-term and long-term bronchodilators
Treatment of asthma and COPD
Mode of administration: mainly inhalation powder (aerosolized or dry), but also nebulizers, intravenous administration, and oral intake
Bronchodilator combinations, e.g., several bronchodilators or a bronchodilator with a corticosteroid

Other drugs to treat asthma or COPD
Smoking cessation products
Alternative medicine

Bronchodilator Drugs market in Gambia has been experiencing growth in recent years.

Customer preferences: The demand for bronchodilator drugs has been increasing in Gambia due to the high prevalence of respiratory diseases. The majority of the population in Gambia are smokers, and this has contributed to the high incidence of respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. As a result, there is a high demand for bronchodilator drugs in the country.

Trends in the market: The Bronchodilator Drugs market in Gambia has been growing due to the increasing prevalence of respiratory diseases. The market is expected to continue growing as the population continues to smoke and the incidence of respiratory diseases increases. The market is also expected to be driven by the increasing availability of generic bronchodilator drugs, which are more affordable than branded drugs.

Local special circumstances: The Bronchodilator Drugs market in Gambia is characterized by a high prevalence of respiratory diseases. This is due to the high smoking rates in the country, as well as the poor air quality in some areas. The market is also characterized by a lack of awareness about respiratory diseases and their treatment, which has led to a high rate of underdiagnosis and undertreatment.

Underlying macroeconomic factors: The Bronchodilator Drugs market in Gambia is influenced by various macroeconomic factors, such as government policies, healthcare expenditure, and economic growth. The government has been implementing policies to improve healthcare access and affordability, which has led to an increase in demand for bronchodilator drugs. Additionally, the country's economic growth has led to an increase in healthcare expenditure, which has also contributed to the growth of the market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.